How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

15,974 results for

HIV Course

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

41. HIV

HIV Top results for hiv - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading (...) history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for hiv The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest

2018 Trip Latest and Greatest

42. Efavirenz/Emtricitabine/Tenofovir disoproxil - HIV

Efavirenz/Emtricitabine/Tenofovir disoproxil - HIV 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact 14 December 2017 EMA/846772/2017 Committee for Medicinal Products for Human Use (CHMP) Assessment report Efavirenz/Emtricitabine/Tenofovir disoproxil Krka International non-proprietary name: efavirenz / emtricitabine / tenofovir (...) Environmental Risk Assessment GC-HS Gas Chromatography head space HDPE High Density Polyethylene HIV Human Immunodeficiency Virus HBV Hepatitis B Virus HPLC High performance liquid chromatography ICH International Conference on Harmonisation of Technical Requirements IR Infrared KF Karl Fischer titration LDPE Low Density Polyethylene Ph. Eur. European Pharmacopoeia RMP Risk Management Plan T max Time of maximum observed plasma concentration; if it occurs at more than one time point, Tmax was defined

2018 European Medicines Agency - EPARs

43. HIV after 40 in rural South Africa: A life course approach to HIV vulnerability among middle aged and older adults. (PubMed)

HIV after 40 in rural South Africa: A life course approach to HIV vulnerability among middle aged and older adults. South Africa has the highest number of people living with HIV in the world (over 6 million) as well as a rapidly aging population, with 15% of the population aged 50 and over. High HIV prevalence in rural former apartheid homeland areas suggests substantial aging with HIV and acquisition of HIV at older ages. We develop a life course approach to HIV vulnerability, highlighting (...) the rise and fall of risk and protection as people age, as well as the role of contextual density in shaping HIV vulnerability. Using this approach, we draw on an innovative multi-method data set collected within the Agincourt Health and Demographic Surveillance System in South Africa, combining survey data with 60 nested life history interviews and 9 community focus group interviews. We examine HIV risk and protective factors among adults aged 40-80, as well as how and why these factors vary among

Full Text available with Trip Pro

2015 Social Science & Medicine

44. Looking upstream to prevent HIV transmission: can interventions with sex workers alter the course of HIV epidemics in Africa as they did in Asia? (PubMed)

Looking upstream to prevent HIV transmission: can interventions with sex workers alter the course of HIV epidemics in Africa as they did in Asia? High rates of partner change in 'upstream' sex work networks have long been recognized to drive 'downstream' transmission of sexually transmitted infections (STIs). We used a stochastic microsimulation model (STDSIM) to explore such transmission dynamics in a generalized African HIV epidemic.We refined the quantification of sex work in Kisumu, Kenya (...) , from the 4-cities study. Interventions with sex workers were introduced in 2000 and epidemics projected to 2020. We estimated the contribution of sex work to transmission, and modelled standard condom and STI interventions for three groups of sex workers at feasible rates of use and coverage.Removing transmission from sex work altogether would have resulted in 66% lower HIV incidence (range 54-75%) and 56% lower prevalence (range 44-63%) after 20 years. More feasible interventions reduced HIV

Full Text available with Trip Pro

2014 AIDS

45. Maintaining and improving quality of care within HIV clinical services

, race, ethnicity, geographical location, religion, socioeconomic status or linguistic or political affiliation; • integrated: providing care that is coordinated across levels and providers and makes available the full range of health services throughout the life-course; and • efficient: maximizing the benefit of available resources and avoiding waste. Source: Why quality universal health coverage? (8).Maintaining and improving quality of care within HIV clinical services, 2019 6 QUALITY MANAGEMENT (...) Maintaining and improving quality of care within HIV clinical services MAINTAINING AND IMPROVING QUALITY OF CARE WITHIN HIV CLINICAL SERVICES JULY 2019 TECHNICAL BRIEF HIV TREATMENT WHO/CDS/HIV/19.17 © World Health Organization 2019 Some rights reserved. This work is available under the Creative Commons Attribution- NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/ licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute

2019 World Health Organisation HIV Guidelines

46. Health technology assessment of a PrEP programme for populations at substantial risk of sexual acquisition of HIV

to uncertainty in the parameters. PrEP effectiveness was the main driver of cost-effectiveness in the model. ? The mean number of people expected to join the programme in year one is 1,705 people (95% CI: 617 to 3,452) based on model calibration to the observed number who enrolled in Scotland’s national programme. On average, 173 HIV infections are estimated to be averted over the course of the first five years in the base case analysis. ? In the first year, PrEP medications alone are estimated to cost €1.1m (...) Health technology assessment of a PrEP programme for populations at substantial risk of sexual acquisition of HIV Health technology assessment of a PrEP programme for populations at substantial risk of sexual acquisition of HIV 14 June 2019 Health technology assessment of a PrEP programme for populations at substantial risk of sexual acquisition of HIV Health Information and Quality Authority Page 2 of 257 Health technology assessment of a PrEP programme for populations at substantial risk

2019 Health Information and Quality Authority

47. British Association for Sexual Health and HIV national guideline for the management of vulvovaginal candidiasis

British Association for Sexual Health and HIV national guideline for the management of vulvovaginal candidiasis British Association for Sexual Health and HIV national guideline for the management of vulvovaginal candidiasis (2019) Guideline Development Group: Cara Saxon (Lead Author), Anne Edwards, Riina Rautemaa- Richardson, Caroline Owen, Bavithra Nathan, Bret Palmer, Clare Wood, Humera Ahmed, Sameena Ahmad, Patient Representatives, Mark FitzGerald (CEG Editor) Clinical Effectiveness Group (...) (CEG), British Association for Sexual Health and HIV (BASHH) NEW IN THE 2019 GUIDELINES Terminology: • The new guidelines refer to ‘acute’ and ‘recurrent’ vulvovaginal candidiasis (VVC) and no longer use the terms ‘uncomplicated’ and ‘complicated’ VVC; the new definitions are felt to be more reflective of how women with VVC typically present to clinical services and are subsequently managed • The elements of complicated VVC where single dose treatments are not always appropriate are still covered

2019 British Association for Sexual Health and HIV

48. Characteristics, Prevention, and Management of Cardiovascular Disease in People Living With HIV: A Scientific Statement From the American Heart Association

Characteristics, Prevention, and Management of Cardiovascular Disease in People Living With HIV: A Scientific Statement From the American Heart Association Characteristics, Prevention, and Management of Cardiovascular Disease in People Living With HIV: A Scientific Statement From the American Heart Association | Circulation Search Hello Guest! Login to your account Email Password Keep me logged in Search December 2019 November 2019 October 2019 September 2019 August 2019 July 2019 June 2019 May (...) 2019 April 2019 March 2019 February 2019 January 2019 This site uses cookies. By continuing to browse this site you are agreeing to our use of cookies. Free Access article Share on Jump to Free Access article Characteristics, Prevention, and Management of Cardiovascular Disease in People Living With HIV: A Scientific Statement From the American Heart Association , MD, MSc, FAHA, Chair , MD, Vice Chair , PhD , MD, MPH, FAHA , MD , MD, MSc , MD , MS , MD, FAHA , MD, MS Matthew J. Feinstein

2019 American Heart Association

49. Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV

Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV UPDATED RECOMMENDATIONS ON FIRST-LINE AND SECOND-LINE ANTIRETROVIRAL REGIMENS AND POST-EXPOSURE PROPHYLAXIS AND RECOMMENDATIONS ON EARLY INFANT DIAGNOSIS OF HIV SUPPLEMENT TO THE 2016 CONSOLIDATED GUIDELINES ON THE USE OF ANTIRETROVIRAL DRUGS FOR TREATING AND PREVENTING HIV INFECTION DECEMBER 2018 INTERIM GUIDELINES HIV TREATMENTUPDATED (...) RECOMMENDATIONS ON FIRST-LINE AND SECOND-LINE ANTIRETROVIRAL REGIMENS AND POST-EXPOSURE PROPHYLAXIS AND RECOMMENDATIONS ON EARLY INFANT DIAGNOSIS OF HIV: INTERIM GUIDELINES SUPPLEMENT TO THE 2016 CONSOLIDATED GUIDELINES ON THE USE OF ANTIRETROVIRAL DRUGS FOR TREATING AND PREVENTING HIV INFECTION DECEMBER 2018WHO/CDS/HIV/18.51 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution- NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https

2019 World Health Organisation HIV Guidelines

50. Short-course antiretroviral therapy in primary HIV infection. (PubMed)

Short-course antiretroviral therapy in primary HIV infection. Short-course antiretroviral therapy (ART) in primary human immunodeficiency virus (HIV) infection may delay disease progression but has not been adequately evaluated.We randomly assigned adults with primary HIV infection to ART for 48 weeks, ART for 12 weeks, or no ART (standard of care), with treatment initiated within 6 months after seroconversion. The primary end point was a CD4+ count of less than 350 cells per cubic millimeter (...) a greater interval between ART initiation and the primary end point the closer that ART was initiated to estimated seroconversion (P=0.09), and 48-week ART conferred a reduction in the HIV RNA level of 0.44 log(10) copies per milliliter (95% CI, 0.25 to 0.64) 36 weeks after the completion of short-course therapy. There were no significant between-group differences in the incidence of the acquired immunodeficiency syndrome, death, or serious adverse events.A 48-week course of ART in patients with primary

Full Text available with Trip Pro

2013 NEJM Controlled trial quality: predicted high

51. Course of disease and clinical outcome of endocarditis in HIV-infected individuals

Course of disease and clinical outcome of endocarditis in HIV-infected individuals Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing

2016 PROSPERO

52. Emtricitabine/tenofovir alafenamide (HIV) - Addendum to Commission A16-30

Emtricitabine/tenofovir alafenamide (HIV) - Addendum to Commission A16-30 1 Translation of addendum A16-58 Emtricitabin/Tenofoviralafenamid (HIV-Infektion) – Addendum zum Auftrag A16-30 (Version 1.0; Status: 10 October 2016). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 10 October 2016 1.0 Commission: A16-58 Version: Status: IQWiG Reports (...) – Commission No. A16-58 Emtricitabine/tenofovir alafenamide (HIV infection) – Addendum to Commission A16-30 1 Addendum A16-58 Version 1.0 Emtricitabine/tenofovir alafenamide – Addendum to Commission A16-30 10 October 2016 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Emtricitabine/tenofovir alafenamide (HIV infection) – Addendum to Commission A16-30 Commissioning agency: Federal Joint Committee

2017 Institute for Quality and Efficiency in Healthcare (IQWiG)

53. Canadian guideline on HIV pre-exposure prophylaxis and nonoccupational postexposure prophylaxis

Canadian guideline on HIV pre-exposure prophylaxis and nonoccupational postexposure prophylaxis E1448 CMAJ | NOVEMBER 27, 2017 | VOLUME 189 | ISSUE 47 © 2017 Joule Inc. or its licensors N ew HIV infections occur every year in Canada, 1 highlighting the need for integrated prevention programs. Pre-exposure pro- phylaxis (PrEP) and nonoccupational postexposure prophy- laxis (nPEP) are two important strategies for preventing HIV that should be considered standard of care and implemented (...) as components of a comprehensive response to the epidemic. Pre-exposure prophylaxis is the use of certain antiretroviral medications by HIV-uninfected per- sons who are at high, ongoing risk of HIV acquisition, beginning before and continuing after potential HIV exposures. Postexposure prophy- laxis (PEP) involves 28 days of antiretroviral medications immediately after a specific HIV exposure, and is “nonoccupational” (nPEP) when used after sexual and injection drug use exposures, rather than acci- dental

2017 CPG Infobase

54. Immune activation and HIV-specific T cell responses are modulated by a cyclooxygenase-2 inhibitor in untreated HIV-infected individuals: An exploratory clinical trial. (PubMed)

no effects were seen on plasma markers of inflammation or tryptophan metabolism. No significant immunological effects of etoricoxib were observed in ART-treated patients. Patients receiving long-term etoricoxib treatment had poorer tetanus toxoid and conjugated pneumococcal vaccine responses than those receiving short-course etoricoxib. Cyclooxygenase-2 inhibitors may attenuate harmful immune activation in HIV-infected patients without access to ART. (...) Immune activation and HIV-specific T cell responses are modulated by a cyclooxygenase-2 inhibitor in untreated HIV-infected individuals: An exploratory clinical trial. Pathologically elevated immune activation and inflammation contribute to HIV disease progression and immunodeficiency, potentially mediated by elevated levels of prostaglandin E2, which suppress HIV-specific T cell responses. We have previously shown that a high dose of the cyclooxygenase-2 inhibitor celecoxib can reduce HIV

Full Text available with Trip Pro

2017 PLoS ONE Controlled trial quality: uncertain

55. HIV and infant feeding in emergencies: operational guidance

HIV and infant feeding in emergencies: operational guidance The duration of breastfeeding and support from health services to improve feeding practices among mothers living with HIV HIV AND INFANT FEEDING IN EMERGENCIES: OPERATIONAL GUIDANCEHIV and infant feeding in emergencies: operational guidance© World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https (...) . HIV and infant feeding in emergencies: operational guidance. Geneva: World Health Organization; 2018. Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris. Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/bookorders. To submit requests for commercial use and queries on rights and licensing, see http://www.who.int/about/licensing. Third-party materials. If you wish to reuse material from this work

2018 World Health Organisation Guidelines

56. Guidelines for the diagnosis, prevention and management of cryptococcal disease in HIV-infected adults, adolescents and children

Guidelines for the diagnosis, prevention and management of cryptococcal disease in HIV-infected adults, adolescents and children More than 1 in 10 HIV-related deaths are as a result of cryptococcal me n i n g i t i s. Three quarters of deaths from cryptococcal meningitis are in sub-Saharan Africa. WHO/CDS/HIV/18.2 POLICY BRIEF WHO / James Oatway: Namibia Living with HIV / AIDS at the Katatura State Hospital in Windhoek, Namibia. GUIDELINES FOR THE DIAGNOSIS, PREVENTION AND MANAGEMENT (...) OF CRYPTOCOCCAL DISEASE IN HIV-INFECTED ADULTS, ADOLESCENTS AND CHILDREN SUPPLEMENT TO THE 2016 CONSOLIDATED GUIDELINES ON THE USE OF ANTIRETROVIRAL DRUGS FOR TREATING AND PREVENTING HIV INFECTION MARCH 2018 HIV TREATMENT 1 Cryptococcal meningitis is by far the commonest manifestation of cryptococcal disease representing 70–90% of HIV-related cryptococcal disease. Other less common disease presentations include pulmonary disease and skin, lymph node and bone involvement. The burden of morbidity and mortality

2018 World Health Organisation HIV Guidelines

57. BHIVA/BASHH guidelines on the use of HIV pre-exposure prophylaxis (PrEP)

was a secondary outcome. At interim review, the DSMB recommended that all study participants should be offered study drug. A total of 23 participants became infected with HIV over the course of the study: three in the daily TDF-FTC group and 20 in the deferred (no-PrEP) group, representing a rate difference in HIV infection of 7.8 per 100 person-years (90% CI 4.3–11.3) The relative risk reduction was 86% (90% CI 64–96%) and the number needed to treat over 1 year to prevent one HIV infection was 13 (90% CI 9 (...) ceasing sexual risk. Participants were followed up every 8 weeks for HIV testing and risk-reduction advice, and every 6 months for sexually transmitted infection (STI) testing for a total of 431 person-years of follow-up. Primary endpoint was HIV infection. At interim review, the placebo group was discontinued and all study participants were offered study drug. Over the course of the study, 16 people became infected with HIV: two in the TDF-FTC group and 14 in the placebo group, representing

2018 British Association for Sexual Health and HIV

58. CHIVA Guidance on Transition for adolescents living with HIV

2016. Available from: http://www.chipscohort.ac.uk/summary_data.asp [Accessed 31.12.2016]. 4. Collins IJ, Foster C, Tostein A, Tookey P, Riordan A, Dunn D, Gibb DM, Judd A. Clinical status of adolescents with perinatal HIV at transfer to adult care in the UK/Ireland. CID in press 2016. 5. Ferrand RA, Corbett EL, Wood R et al. AIDS among older children and adolescents in Southern Africa: projecting the time course and magnitude of the epidemic. AIDS 2009; 23(15): 2039-46. 6. Judd A, Ferrand R (...) CHIVA Guidance on Transition for adolescents living with HIV 1 CHIVA Guidance on Transition for adolescents living with HIV Authors: Caroline Foster Date of preparation: September 2010 Date reviewed: February 2017 Next review date: February 2019 This document replaces 2 previous CHIVA documents: “Guidance on transition and long term follow up services for adolescents with HIV infection acquired in infancy”, Melvin et al 2005. “Growing up, Gaining independence: Principles for transitional care

2017 The Children's HIV Association

59. HIV Pre-Exposure Prophylaxis with Emtricitabine/Tenofovir Disoproxil Fumarate — Regulatory and Reimbursement Policies

-risk sexual behaviours individuals who use stimulant drugs associated with high-risk behaviours, such as methamphetamine individuals diagnosed with at least one anogenital STI in the last year individuals who have been prescribed non-occupational post-exposure prophylaxis (nPEP) who demonstrate continued high-risk behaviour or have used multiple courses of nPEP In summary, there is no single program or set of criteria for providing HIV PrEP in the US. All US programs identified in this report (...) continued high‑risk behaviour or have used multiple courses of nPEP England (draft) 40 Individuals considered to be at substantial risk of HIV acquisition include those who are: MSMs or transgender persons who are currently HIV-negative and who are clinically assessed to be at high risk of HIV acquisition through fulfilling the following criteria: have a documented confirmed HIV-negative test during an earlier episode of care in the preceding year (i.e., 42 days to 365 days ago) report condomless

2017 Canadian Agency for Drugs and Technologies in Health - Environmental Scanning

60. HIV Pre-Exposure Prophylaxis with Emtricitabine/Tenofovir Disoproxil Fumarate — Regulatory and Reimbursement Policies

-risk sexual behaviours individuals who use stimulant drugs associated with high-risk behaviours, such as methamphetamine individuals diagnosed with at least one anogenital STI in the last year individuals who have been prescribed non-occupational post-exposure prophylaxis (nPEP) who demonstrate continued high-risk behaviour or have used multiple courses of nPEP In summary, there is no single program or set of criteria for providing HIV PrEP in the US. All US programs identified in this report (...) continued high‑risk behaviour or have used multiple courses of nPEP England (draft) 40 Individuals considered to be at substantial risk of HIV acquisition include those who are: MSMs or transgender persons who are currently HIV-negative and who are clinically assessed to be at high risk of HIV acquisition through fulfilling the following criteria: have a documented confirmed HIV-negative test during an earlier episode of care in the preceding year (i.e., 42 days to 365 days ago) report condomless

2017 Canadian Agency for Drugs and Technologies in Health - Environmental Scanning

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>